Overview

Phase 3 and Extensional Study of Besifovir

Status:
Active, not recruiting

Trial end date:
2023-01-01

Target enrollment:

Participant gender:

Summary

To prove that a study drug is noninferior to a control drug with a proportion of subjects who showed HBV DNA undetected (less than 400 copies/mL (69 IU/mL)) at the 48th week after 48-week administration of Besifovir 150 mg, or Tenofovir 300 mg as a control drug to chronic hepatitis B patients

Phase:

Phase 3

Details

Lead Sponsor:

IlDong Pharmaceutical Co Ltd

Treatments:

Tenofovir